Targeting the replication stress response in cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Conventional chemotherapies induce DNA damage, causing toxicity in both tumor and healthy proliferative tissues.
• Targeted therapies aim to selectively eliminate cancer cells, minimizing off-target effects.
• The replication stress response (RSR) is a critical DNA damage response pathway that prevents genomic instability during DNA replication.

Purpose of the Study:

• To review the molecular mechanisms of the replication stress response (RSR).
• To elucidate the rationale for targeting RSR in cancer treatment.
• To discuss the optimal clinical application of RSR inhibitors, including patient selection and combination strategies.

Main Methods:

• Review of molecular mechanisms of RSR.
• Analysis of preclinical in vitro and in vivo studies.
• Evaluation of clinical development phases for RSR kinase inhibitors (ATR, CHK1, WEE1).

Main Results:

• RSR involves key kinases (ATR, CHK1, WEE1) that manage DNA replication stress.
• Inhibitors targeting these RSR kinases are in various stages of clinical development.
• Preclinical data support the potential of RSR-targeted therapies in specific cancer contexts.

Conclusions:

• Targeting RSR presents a promising strategy for selective cancer therapy.
• Understanding RSR's molecular role is crucial for effective therapeutic development.
• Future clinical success depends on strategic patient selection and combination therapies.